DRMAW Dermata Therapeutics, Inc.
Price Chart
Executive Summary
The SEC declared effective Dermata Therapeutics' S-3 shelf registration (File No. 333-291740) on May 29, 2026, allowing the company to offer and sell up to $100,000,000 in common stock, preferred stock, warrants, debt securities, subscription rights, and units from time to time. This creates a significant dilution overhang for the company's common stock and warrants (DRMA/DRMAW), as the shelf can be drawn down at management's discretion without further shareholder approval.
Actionable Insight
The shelf being effective means Dermata can conduct an underwritten offering at any time. Given the company's micro-cap status and the massive $100M shelf relative to its market cap, the overhang is severe. Traders should watch for a prospectus supplement (424B5) indicating an actual takedown — that event would likely drive DRMA and DRMAW sharply lower. Until then, the overhang alone should cap any upside.
Key Facts
- Effectiveness date: May 29, 2026
- Shelf registration amount: $100,000,000
- Securities registered: common stock, preferred stock, warrants, debt securities, subscription rights, units
- Company's common stock last traded at $1.24/share and warrants at $0.0139/warrant on May 21, 2026
- This is a new shelf (File No. 333-291740), separate from the January 2026 S-3 resale shelf (File No. 333-291740 was the new shelf; the January S-3 had a different file number)
Financial Impact
Up to $100,000,000 in potential dilution — at the current $1.24 common stock price, this represents approximately 80.6 million shares of potential dilution, dwarfing the current market cap.
Risk Factors
- Imminent dilutive offering — the company has a history of using shelf registrations to raise capital
- Warrant holders (DRMAW) face extreme dilution risk as any common stock offering would further depress the already low $0.0139 warrant price
- No disclosed use of proceeds — typical for a general shelf, but suggests capital raise is likely given the company's cash needs as a clinical-stage biotech
Market Snapshot
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001810 |
| Document: 9999999995-26-001810-index.html | 9999999995-26-001810 |
| Document: 9999999995-26-001810.txt | 9999999995-26-001810 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
12d ago
|
EFFECT
| $0.0183 $0.0183 | · 0.00% | ▼ −2.75% | $0.0183 (−0.00%) |
|
May 27, 2026
16d ago
|
8-K
| $0.0183 $0.0183 | · 0.00% | ▼ −0.32% | $0.0183 (+0.00%) |
|
Apr 17, 2026
8w ago
|
DEFA14A
| $0.0183 $0.0183 | · 0.00% | ▼ −0.91% | $0.0183 (+0.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access